| |
Possible AD
|
Non-AD
|
|---|
|
A. Analysis of association of TBI with development of dementia with possible AD
|
|
Age
|
80.9 ± 6.7
|
70.1 ± 10.1
|
|
Sex
|
|
Male
|
62,951
|
556,525
|
|
Female
|
1388
|
31,920
|
|
Ethnicity
|
|
Caucasian
|
51,884
|
445,237
|
|
African American
|
6779
|
97,782
|
|
Hispanic
|
4565
|
30,581
|
|
Other
|
1111
|
14,845
|
|
B. Analysis of association of medications with development of dementia with possible AD after TBI occurrence
|
|
Age
|
76.9 ± 8.5
|
64.5 ± 9.8
|
|
Sex
|
|
Male
|
310
|
5663
|
|
Female
|
17
|
710
|
|
Ethnicity
|
|
White
|
228
|
4431
|
|
African American
|
35
|
1243
|
|
Hispanic
|
57
|
506
|
|
Other
|
7
|
193
|
|
Medication
|
|
No med
|
92
|
1957
|
|
ACEI
|
47
|
644
|
|
Beta blocker
|
35
|
868
|
|
Metformin
|
29
|
403
|
|
Statin
|
57
|
1105
|
|
ACEI + beta blocker
|
15
|
262
|
|
ACEI + metformin
|
2
|
133
|
|
ACEI + statin
|
14
|
359
|
|
Beta blocker + statin
|
21
|
394
|
|
Beta blocker + metformin
|
3
|
89
|
|
Metformin + statin
|
12
|
159
|
- Note: “Medication” designates single and combination patterns of the four target medication classes. Subjects who were prescribed medications other than the target medication classes in the dataset are included as “No med” group. Subjects who were on any of those medication classes at the start of study window or were prescribed three or four of those classes are excluded
